- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04653532
Mobile Health to Enhance Exercise in Type 2 Diabetes (MOTIVATET2D)
Mobile Health Biometrics to Enhance Exercise and Physical Activity Adherence in Type 2 Diabetes: A Pilot Randomized Trial
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Ali McManus, PhD
- Telefoonnummer: 250-807-8192
- E-mail: ali.mcmanus@ubc.ca
Studie Contact Back-up
- Naam: Matthew S Cocks, PhD
- Telefoonnummer: 0151 904 6243
- E-mail: M.S.Cocks@ljmu.ac.uk
Studie Locaties
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1V1V7
- Werving
- University of British Columbia
-
Contact:
- Jonathan Low
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosed with T2D within the previous 5-24 months
- Male or Female
- Aged 40-75
- Treat diabetes with only Metformin or lifestyle modifications (diet and exercise)
- For those prescribed Metformin: have used a stable dose for 3-months or more
Exclusion Criteria:
- Aged under 40 or over 75
- Glycated hemoglobin level (HbA1c) more than 10% (>86mmol/mol)
- Blood pressure higher than 160/110 mmHg
- Treat diabetes with an antidiabetic drug other than Metformin (Sulfonylureas, Thiazolidinedione, dipeptidylpeptidase-4 inhibitors, sodium glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonist, Acarbose, meglitinides)
- Prescription of Insulin
- Unstable angina (frequent chest pain)
- Myocardial infarction (heart attack) within the previous 3 months
- Transient ischemic attack (TIA) within the previous 6 months
- Heart failure ≥class 2
- Arrhythmia
- Inability to increase activity
- Pregnancy or planning to become pregnant
- Less than 6 months post childbirth or stopped breastfeeding less than 1 month ago
- Not owning a smartphone/ or having no data plan or access to WiFi
- currently meeting the recommended exercise guidelines (150 min of moderate intensity exercise per week).
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: mHealth Technology
Participants in this group (Mobile health technology (mHealth)) will receive the same 6-month exercise and physical activity programme supported by an exercise specialist, but participants in this group will also receive a fitness watch that links to a mobile phone application (App).
|
A 6 month exercise and physical activity programme supported by an exercise specialist
A fitness watch that links to a mobile phone application (App) which enables the exercise specialist to provide greater support and feedback throughout the programme
Andere namen:
|
|
Actieve vergelijker: Exercise Counselling
Participants in this group (Exercise Counselling) will complete a 6-month structured exercise and physical activity programme supported by regular contact with an exercise specialist.
|
A 6 month exercise and physical activity programme supported by an exercise specialist
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Determine the number of adults with newly diagnosed T2D that are eligible to participate in the trial
Tijdsspanne: 0-12 months
|
Information will be collected on: - The number of patients approached and reasons for not joining the study |
0-12 months
|
|
The number of these adults with newly diagnosed T2D who would be willing to take part in this trial
Tijdsspanne: 0-12 months
|
Information will be collected on: - The number of patients who actually enroll |
0-12 months
|
|
The characteristics of these adults with newly diagnosed T2D who are willing to take part in the trial
Tijdsspanne: 0-12 months
|
Information will be collected on: - Patient gender, age, and how patients are currently treating their T2D |
0-12 months
|
|
The number and percentage of participants retained at 12-months.
Tijdsspanne: 0-12 months
|
Information will be collected on: - Number and percentage of patients attending at 12-month follow up and reasons for drop-out. |
0-12 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Adherence to exercise
Tijdsspanne: 0 months, 0-6 months, 0-12 months
|
Adherence to structured exercise assessed through monthly exercise questionnaire (GLTEQ)
|
0 months, 0-6 months, 0-12 months
|
|
Change in glycaemic control
Tijdsspanne: 0 months, 0-6 months, 0-12 months
|
Glycated hemoglobin (HbA1c), flash glucose monitoring
|
0 months, 0-6 months, 0-12 months
|
|
Change in body composition
Tijdsspanne: 0 months, 0-6 months, 0-12 months
|
Height (meters) and weight (kilograms) will be aggregated to arrive at one reported BMI value (kg/m^2)
|
0 months, 0-6 months, 0-12 months
|
|
Change in weight
Tijdsspanne: 0 months, 0-6 months, 0-12 months
|
Weight (kilograms)
|
0 months, 0-6 months, 0-12 months
|
|
Change in waist circumference
Tijdsspanne: 0 months, 0-6 months, 0-12 months
|
Waist circumference (centimeters)
|
0 months, 0-6 months, 0-12 months
|
|
Change in blood pressure
Tijdsspanne: 0 months, 0-6 months, 0-12 months
|
Blood pressure taken with a cuff
|
0 months, 0-6 months, 0-12 months
|
|
Change in blood lipids
Tijdsspanne: 0 months, 0-6 months, 0-12 months
|
Total cholesterol, high-density lipoprotein, triglycerides, low-density lipoprotein
|
0 months, 0-6 months, 0-12 months
|
|
Diabetes related quality of life
Tijdsspanne: 0 months, 0-6 months, 0-12 months
|
SF-12 Health Survey and Diabetes Treatment Satisfaction Questionnaire used to assess diabetes related quality of life
|
0 months, 0-6 months, 0-12 months
|
|
Behavioural regulation in exercise
Tijdsspanne: 0 months, 0-6 months, 0-12 months
|
Assessed using the Behavioural Regulation in Exercise Questionnaire
|
0 months, 0-6 months, 0-12 months
|
|
Patient rapport with counsellor
Tijdsspanne: 0 months, 0-6 months, 0-12 months
|
Assessed using the Patient Rapport with Counsellor Questionnaire
|
0 months, 0-6 months, 0-12 months
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Acceptability and feasibility of the wearable intervention to patients
Tijdsspanne: 0-6 months, 0-12 months
|
Post-intervention patient questionnaire that will assess the acceptability of the wearable intervention and exposure to other wearable technologies
|
0-6 months, 0-12 months
|
|
Acceptability and feasibility of patients continuing the intervention on their own
Tijdsspanne: 0-6 months, 0-12 months
|
Follow-up patient questionnaire investigating anticipated barriers and facilitators to continuing the intervention
|
0-6 months, 0-12 months
|
|
Pilot methods for collecting outcome measures
Tijdsspanne: Approx. 1 month after baseline
|
Early acceptability questionnaire investigating the acceptability of the measurement instruments and their ease of use.
|
Approx. 1 month after baseline
|
|
Ensure that our plans for recruitment, randomisation, treatment, and follow-up are acceptable to patients
Tijdsspanne: 0-12 months
|
Post intervention patient questionnaire investigating the acceptability of the recruitment and randomisation process and the measurement instruments
|
0-12 months
|
|
Determine availability and completeness of economic data
Tijdsspanne: 0 months, 0-6 months, 0-12 months
|
5-level EQ-5D Questionnaire
|
0 months, 0-6 months, 0-12 months
|
|
Determine healthcare usage
Tijdsspanne: 0 months, 0-6 months, 0-12 months
|
Questionnaire assessing healthcare usage in the last 12 weeks
|
0 months, 0-6 months, 0-12 months
|
Medewerkers en onderzoekers
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- H20-01936
- 20/SS/0101 (Andere identificatie: South East Scotland Research Ethics Committee)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Diabetes mellitus, type 2
-
Instituto Nacional de Ciencias Medicas y Nutricion...Actief, niet wervend
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... en andere medewerkersWervingType 2 diabetes | Diabetes mellitus type 2Turkije (Türkiye)
-
Endogenex, Inc.Nog niet aan het wervenDiabetes mellitus, type 2 | Suikerziekte | Diabetes mellitus type 2 | Type 2 diabetes | Type 2 diabetes
-
University of ChicagoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... en andere medewerkersWervingDiabetes mellitus type 2 (T2DM) | Diabetes noodVerenigde Staten
-
Dokuz Eylul UniversityActief, niet wervendDiabetes mellitus type 2 (T2DM) | Activering van de patiënt | Diabetes Zelfmanagement | Diabetes Mellitus (DM)Kalkoen
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationWervingDiabetes mellitus type 2 met complicatiesIndië
-
SanofiVoltooidDiabetes mellitus type 1 - Diabetes mellitus type 2Hongarije, Russische Federatie, Duitsland, Polen, Japan, Verenigde Staten, Finland
-
Endogenex, Inc.Nog niet aan het wervenDiabetes mellitus, type 2 | Suikerziekte | Type 2 diabetes | Diabetes mellitus type 2 (T2DM) | Type 2 diabetes
-
El Katib HospitalNog niet aan het wervenDiabetes mellitus type 2 (T2DM)
-
He Eye HospitalNog niet aan het werven